Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com
by Teresa Graham · The Cerbat GemStockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research report released on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The company has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Featured Stories
- Five stocks we like better than Genocea Biosciences
- What is a Stock Market Index and How Do You Use Them?
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- How to Use the MarketBeat Excel Dividend Calculator
- Applied Materials Market Capitulates: Now is the Time to Buy
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Ultra-High Dividend Yield Stocks for the New Year